Mankind Pharma Ltd

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a recent price decline, the pharmaceutical company’s futures and options contracts have attracted increased volumes, reflecting a complex interplay of directional bets and volatility.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a recent price decline, the stock’s derivatives market reveals intriguing directional bets that merit close attention from investors and analysts alike.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a recent price decline, the stock’s derivatives market shows signs of increased speculative interest, raising questions about potential directional bets and future price movements.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a recent price decline, the pharmaceutical company’s futures and options contracts have attracted increased volumes, reflecting a complex interplay of directional bets and volatility in the stock.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a recent price decline and increased volatility, the pharmaceutical company’s futures and options contracts have attracted substantial volume, reflecting evolving directional bets and strategic plays by market participants.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a recent price decline, the pharmaceutical company’s futures and options contracts have seen a 16.8% increase in open interest, reflecting growing speculative interest and potential directional bets amid volatile trading conditions.

Mankind Pharma Ltd experienced a notable decline today, touching an intraday low of Rs 2445.45, reflecting a 5.1% drop as the stock faced significant price pressure and heightened volatility within the Pharmaceuticals & Biotechnology sector.

Mankind Pharma Ltd., one of India's leading pharmaceutical companies with a market capitalisation of ₹1,06,503 crores, reported consolidated net profit of ₹568.06 crores for Q1 FY27 ended June 2026, marking a modest sequential growth of 2.47% from ₹554.35 crores in Q4 FY26. On a year-on-year basis, the company delivered impressive growth of 29.60%, substantially outpacing the ₹438.32 crores posted in Q1 FY26. However, the stock reacted negatively, declining 0.60% to ₹2,576.95 following the results announcement, as investors digested margin compression concerns despite robust topline expansion.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 15.2% surge in open interest in its derivatives segment, signalling increased market participation and potential shifts in investor positioning despite a modest price decline over recent sessions.

Mankind Pharma Ltd has witnessed a notable 14.5% increase in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite a modest price decline over the past two sessions, the surge in open interest and volume suggests evolving directional bets and increased investor participation in this mid-cap pharmaceutical stock.

Mankind Pharma Ltd has witnessed a notable surge in open interest in its derivatives segment, signalling increased investor interest and potential directional bets. The pharmaceutical mid-cap, trading close to its 52-week high, is showing signs of robust market positioning with rising volumes and improved mojo ratings, suggesting a bullish outlook among traders and investors alike.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased investor interest and potential directional bets. The stock’s latest open interest rose by 11.46% to 16,201 contracts, accompanied by robust volume and rising investor participation, suggesting a bullish undertone despite a minor price dip of 0.45% on 30 Jul 2026.

Mankind Pharma Ltd has been upgraded from a Hold to a Buy rating, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality assessments. The upgrade, effective from 29 July 2026, is underpinned by robust quarterly results, bullish technical signals, and sustained long-term growth, positioning the mid-cap pharmaceutical company favourably against its peers and broader market benchmarks.

Mankind Pharma Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling a transition from mildly bullish to a more confident bullish stance. Despite a slight dip in the latest session, the stock’s underlying technical framework suggests strengthening momentum, supported by positive moving averages and bullish MACD readings on the weekly chart.

Mankind Pharma Ltd has witnessed a notable 14.48% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this surge, the stock underperformed its sector and broader indices, reflecting a complex interplay of bullish and cautious sentiments among traders.

Mankind Pharma Ltd has witnessed a notable 13.0% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this surge, the stock underperformed its sector on 29 Jul 2026, reflecting a complex interplay of bullish and bearish sentiments among traders.

Mankind Pharma Ltd has witnessed a notable 12.63% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a slight dip in the stock price, the surge in open interest alongside rising volumes suggests evolving directional bets within the Pharmaceuticals & Biotechnology sector.